This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Methods We conducted a comprehensive search for articles on PubMed and Embase using search strategies which yielded 4,061 articles. After full-text screening, 66 articles were included for systematic review, and 62 articles were further selected for meta-analysis. Overall, 55 (83.3%) studies were at low risk of bias.
Old ‘NSTEMI’ A history of coronary artery disease and a stent to the same territory further increases pre-test likelihood of acute coronary occlusion, including in-stentthrombosis. The patient had a history of ‘NSTEMI’ a decade prior, with an RCA stent. Does this change your interpretation?
7 The use of antiplatelet agents to prevent stentthrombosis, moderate- to high-dose statin therapy after acute coronary syndromes, or antihypertensive agents in asymptomatic patients may all be perceived by patients as not providing benefit because they may not feel the effects.8
The near-immediate or instant feedback learning process by which the heart responds to any new invasive procedural variation facilitates each new change; be it drug-eluting stent, drug-coated balloon, or both in different combinations and permutations.
I would expect that a stent would be placed. The angiogram showed an open artery with 95% stenosis and thrombosis and it was stented. I would expect TIMI-3 flow (normal flow, no persistent ischemia) with a culprit in the RCA (or possibly Circumflex). They were interpreted as completely NORMAL!! Jesse McLaren et al.
Here is the classic article on continuous 12-lead monitoring (in full text) showing that the ECG is a much more reliable indicator of re-occlusion than are symptoms. Here is another classic article. It was stented. It is well documented with continuous 12-lead monitoring that acute re-occlusion is frequently asymptomatic.
Databases were searched for relevant articles published before 10 November 2023. Similarly, all-cause mortality, cardiovascular mortality, stentthrombosis, and acute renal insufficiency did not show significant differences between two groups.
That, it was possible to treat atherosclerotic coronary artery disease with an updated Andreas Grüntzig’s balloon alone, without the safety net and comfort of implanting a single stent. Three interactive cases were treated with the drug-coated balloon and all patients were same-day discharged.
In the early years of percutaneous coronary intervention (PCI), studies indicated a heightened risk of major adverse cardiac events (MACE) in patients with reduced left ventricular ejection fraction (LVEF), involving outcomes such as death, Q-wave myocardial infarction (MI), stentthrombosis, and repeat revascularization. Am Heart J.
The primary outcome was major adverse cardiac and cerebrovascular event (MACCE), namely a composite of death from cardiovascular causes, myocardial infarction (MI), stroke, stentthrombosis within 12 month. The secondary outcome was Bleeding Academic Research Consortium (BARC) scale bleeding events within 12 months.
Primary endpoint of systematic review and meta-analysis is the NACE (Net Adverse Cardiac Events) and secondary are MACE (Major Adverse Cardiac Events), mortality, bleedings, myocardial infarction and stentthrombosis. Subgroup analyses included studies using only ticagrelor-based regimens and three-months duration of DAPT.
0.85, P = 0.004), target vessel revascularization (TVR) (P = 0.01), target lesion revascularization (TLR) (P = 0.03) and stentthrombosis (ST) (P = 0.002) in the experimental group (IVUS-guidance) was lower than that in the control group (non-IVUS-guidance). The results showed that the incidence of MACE (RR: 0.63, 95% CI: 0.49–0.82,
After stent deployment, we often see improvement in the ST-T within seconds or minutes. Here is the final angiogram following placement of a stent in the ostial RCA. 2:04 PM, post stent deployment You can see that even after complete restoration of flow, the ECG still looks terrible, V most of all.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
59 
Let's personalize your content